Open an account

Lineage Cell Therapeutics

LCTX · NYSE American

$0.9726+$0.0198 (+2.08%)TodayMarket closed ·
Prev close $0.9528

About LCTX

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 72 full-time employees. The firm programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).

Employees
72
Headquarters
Carlsbad, California
Listed
Mar 5, 1992
Sector
Health Care
Industry
Biotechnology
Website
lineagecell.com

LCTX key statistics

Market cap
245.98M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.61M
Volume
1.63M
Open price
$0.9508
High today
$1.01
Low today
$0.9508
52 Week high
$2.09
52 Week low
$0.8823

Lineage Cell Therapeutics (LCTX) at a glance

Lineage Cell Therapeutics (LCTX) last traded at $0.9726, with a market cap of 245.98M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.9508 and $1.01. The current price is 2.3% above the day's low and 3.7% below its high.

Volume so far is 1.63M shares, in line with the average of 1.61M shares a day.

Over the past year Lineage Cell Therapeutics has ranged from $0.8823 to $2.09, and now sits 7% of the way up that range.

Lineage Cell Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported $0.01 per share against an estimate of -$0.0289.

The average analyst price target is $5.61, 476.8% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $5.61
Low
$3.03
Now
$0.9726
High
$9.45

LCTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 77.6% on average.

  1. Q3 FY24: reported -$0.02 per share against an estimate of -$0.0437
  2. Q4 FY24: reported -$0.01 per share against an estimate of -$0.0087
  3. Q1 FY25: reported -$0.02 per share against an estimate of -$0.0255
  4. Q2 FY25: reported -$0.07 per share against an estimate of -$0.0277
  5. Q3 FY25: reported -$0.13 per share against an estimate of -$0.0262
  6. Q4 FY25: reported $0.00 per share against an estimate of -$0.0527
  7. Q1 FY26: reported -$0.03 per share against an estimate of -$0.0204
  8. Q2 FY26: reported $0.01 per share against an estimate of -$0.0289

LCTX news

  • Press releaseBusiness Wire

    Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform

  • Press releaseBusiness Wire

    Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

  • Press releaseBusiness Wire

    Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

  • Press releaseBusiness Wire

    Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease

  • Press releaseBusiness Wire

    Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

  • Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call

  • Press releasePRNewswire

    Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

  • Press releaseBusiness Wire

    Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Similar companies

Companies in the same industry as Lineage Cell Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.